Novartis Home

At Novartis, we are reimagining medicine

Transmission electron microscopic image of an isolate from a case of COVID-19

Novartis COVID-19 Information Center

Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.

Enter

Novartis at ASCO

Latest oncology resources and news surrounding Novartis data featured at American Society of Clinical Oncology (ASCO).

Latest News

Jun 05, 2020

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
Jun 04, 2020

Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis
Jun 02, 2020

Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
May 29, 2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Media releases

Novartis on Twitter

Novartis Home

At Novartis, we are reimagining medicine

Novartis COVID-19 Information Center

Novartis at ASCO

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma

Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis

Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery